

July 22, 2021

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Through: BSE Listing Centre

Scrip Code: 540788
Security ID: ASPIRA

Dear Sir/Madam,

**Sub: Reconciliation of Share Capital Audit Report for quarter ended June 30, 2021
for under Regulation 76 of Securities and Exchange Board of India (Depositories
and Participants) Regulations, 2018**

Dear Sir/Madam,

Pursuant to Regulation 76 of SEBI ((Depositories and Participants) Regulations, 2018, we are enclosing herewith the Reconciliation of Share Capital Audit Report of the Company issued by S.K. Pandey, Practicing Company Secretary, for the quarter ended June 30, 2021.

Kindly take the same on record.

Thanking You.

Yours faithfully,

For Aspira Pathlab & Diagnostics Limited



Devyangi Patel
Company Secretary



Encl: As above

SANTOSHKUMAR KAMLESHCHANDRA PANDEY

Practicing Company Secretary ACS No: 8546/ COP No: 5484

Add: Bunglow No 14 Rajvilas Haveli Kothi CHS Ltd, Ghodbunder Road, Chitalnar, Manpada, Thane – 400610 Maharashtra

Mob: +91 9821051427, E-mail: pandeysk2004@yahoo.co.in



**RECONCILIATION OF SHARE CAPITAL AUDIT REPORT FOR
THE QUARTER ENDED 30th June 2021**

I have examined the Register of Members, beneficiary details furnished by the Depositories and other records/ documents maintained by **M/s. Aspira Pathlab & Diagnostics Limited** (hereinafter referred to as “the Company”) for issuing this certificate, in accordance with Regulations 76 of SEBI (Depositories & Participants) Regulations, 2018.

In our opinion and to the best of our knowledge and according to the information and explanations given to us and based on such verification as considered necessary by us, we hereby certify that:

The total number of equity shares issued/ paid-up, listed and admitted capital as on **30th June 2021** is given in below table: -

1.	For Quarter ended	:	30 th June, 2021	
2.	ISIN	:	INE500C01017	
3.	Face Value	:	Rs. 10/-	
4.	Name of the Company	:	Aspira Pathlab & Diagnostics Limited	
5.	Registered Office	:	Flat No. 2, R.D. Shah Building, Shraddhanand Road, Opposite Ghatkopar Railway Station, Ghatkopar (West), Mumbai - 400086	
6.	Correspondence Address	:	6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar W, Mumbai 400086 MH IN	
7.	Telephone No & Fax No.	:	Registered Office Tel No: 022-71975756 Corporate Office Tel No: +91 8928379815	
8.	Email Address	:	info@aspiradiagnostics.com	
9.	Name of Stock Exchange where the Company's securities are listed	:	BSE Ltd	
			Number of Shares	% of Total Issued Capital
10.	Issued Capital (No. of Shares)	:	*1,57,93,000 (1,02,93,000 equity shares of Rs. 10/- each and 55,00,000, 9% Non-Convertible, Non-Cumulative, Non-Participating redeemable preference shares (“NCRPS”) of Rs. 10/-)	100.00
11.	Listed Capital			
	BSE Limited	:	1,02,93,000	65.17
12.	Held in Dematerialized from in CDSL (No. of shares)	:	62,81,423	39.77
13.	Held in Dematerialized from in NSDL (No. of shares)	:	39,62,397	25.09
14.	Physical (No. of shares)	:	49,180	0.31
15.	Total No. of Shares (12+13+14)	:	1,02,93,000	65.17

SANTOSHKUMAR KAMLESHCHANDRA PANDEY

Practicing Company Secretary ACS No: 8546/ COP No: 5484

Add: Bunglow No 14 Rajvilas Haveli Kothi CHS Ltd, Ghodbunder Road, Chitalnar, Manpada, Thane – 400610 Maharashtra

Mob: +91 9821051427, E-mail: pandeysk2004@yahoo.co.in



16.	Reasons for difference, if any, between (10 & 11), (10 & 15), (11 & 15)	:	* The Company has allotted 55,00,000 (9% Non-Convertible, Non-Cumulative, Non-Participating redeemable preference shares (“NCRPS”)) of Rs. 10/- each on 24 th August, 2018, & the same are not listed with any stock exchange.				
17.	Certifying the details of changes in share capital during the quarter under consideration as per table below						
	Particulars	No. of shares	Applied/ Not applied for Listing	Listed on Stock Exchange	Whether intimated to CDSL	Whether intimated to NSDL	In-Principle Approval pending from Stock Exchange
NIL							
18.	Register of members is updated, if not, updated up to which date	:	Yes				
19.	Reference of previous quarter with regard to excess dematerialization shares, if any	:	NIL				
20.	Has the Company resolved the matter mentioned in point no. 19 above in the current quarter? if not, reason why?	:	Not Applicable				
21.	Mentioned the total no. of requests, if any confirmed after 21 days and the total no. of requests pending beyond 21 days with reasons for delay.						
	Total No. of Demat Request	No. of Request	No. of Shares	Reason for delay			
	Confirmed after 21 days (from the date of receipt of DRF by RTA)	NIL	NIL	NIL			
	Pending for more than 21 days (from the date of receipt of DRF by RTA)	NIL	NIL	NIL			
22.	Name, Telephone & Fax no. of the Compliance Officer of the Company	:	Devyangi Patel (Company Secretary/ Compliance Officer) Membership No.: A52176 Tel No: +91 9004292330 Email: devyangi.patel@aspiradiagnostics.com				

